haematology oncology
Khorana Score for VTE in Cancer
Predicts risk of VTE in cancer patients starting chemotherapy. Validated for ambulatory cancer patients.
Score interpretation
Low Risk 0
Low risk of VTE (~0.3–0.8% at 2.5 months)
→ No prophylaxis recommended routinely
Intermediate Risk 1–2
Intermediate risk of VTE (~2%)
→ Consider prophylaxis based on clinical judgement
High Risk 3–6
High risk of VTE (~6.7%)
→ Prophylactic anticoagulation recommended (LMWH or DOAC)
Interpretation bands for the Khorana Score. Apply clinical judgement and local guidance.
References
- Khorana AA et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
- Folinic Acid (Calcium Folinate / Leucovorin) · Antidote / Chemotherapy Support
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Methotrexate · Chemotherapy / Immunosuppressant — Head and Neck / Granulomatosis
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.